

40072-0026

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)

10/560,280

INTERNATIONAL APPLICATION NO.

PCT/JP2004/008224

INTERNATIONAL FILING DATE

June 11, 2004

PRIORITY DATE CLAIMED

June 13, 2003

TITLE OF INVENTION

**RECOMBINANT ADENO-ASSOCIATED VIRUS VECTOR FOR TREATMENT OF ALZHEIMER DISEASE**

APPLICANT(S) FOR DO/EO/US

Takeshi TABIRA; Hideo HARA

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1.  This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2.  This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3.  This express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4.  The US has been elected (Article 31).
5.  A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a.  is attached hereto (required only if not communicated by the International Bureau).
  - b.  has been communicated by the International Bureau.
  - c.  is not required, as the application was filed in the United States Receiving Office (RO/US).
6.  A English language translation of the International Application as filed (35 U.S.C. 371(c)(2))
  - a.  is attached hereto.
  - b.  has been previously submitted under 35 U.S.C. 154(d)(4).
7.  Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - a.  are attached hereto (required only if not communicated by the International Bureau).
  - b.  had been communicated by the International Bureau.
  - c.  have not been made; however, the time limit for making such amendments has NOT expired.
  - d.  have not been made and will not be made.
8.  An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9.  An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10.  An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

**Items 11 to 20. below concern document(s) or information included:**

11.  An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12.  An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included
13.  A preliminary amendment.
14.  An Application Data Sheet under 37 CFR 1.76.
15.  A substitute specification.
16.  A power of attorney and/or address letter.
17.  A computer-readable form of the sequence listing in accordance with PCT Rule 132 and 37 CFR 1.821-1825
18.  A second copy of the published international application under 35 U.S.C. 154(d)(4)
19.  A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20.  Other items or information: Declaration and Power of Attorney

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE FORM PTO-1390 (REV. 02-2005)		ATTORNEY'S DOCKET NUMBER <b>40072-0026</b>
<b>TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371</b>		U.S. APPLICATION NO. (if known, see 37 CFR 1.5) <b>10/560,280</b>
INTERNATIONAL APPLICATION NO. <b>PCT/JP2004/008224</b>	INTERNATIONAL FILING DATE <b>June 11, 2004</b>	PRIORITY DATE CLAIMED <b>June 13, 2003</b>
TITLE OF INVENTION <b>RECOMBINANT ADENO-ASSOCIATED VIRUS VECTOR FOR TREATMENT OF ALZHEIMER DISEASE</b>		
APPLICANT(S) FOR DO/EO/US <b>Takeshi TABIRA; Hideo HARA</b>		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<p>1. <input type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input checked="" type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</p> <p>4. <input type="checkbox"/> The US has been elected (Article 31).</p> <p>5. <input type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))        a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).        b. <input type="checkbox"/> has been communicated by the International Bureau.        c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</p> <p>6. <input type="checkbox"/> A English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).        a. <input type="checkbox"/> is attached hereto.        b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</p> <p>7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))        a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).        b. <input type="checkbox"/> had been communicated by the International Bureau.        c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.        d. <input type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p>		
Items 11 to 20. below concern document(s) or information included:		
<p>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included</p> <p>13. <input checked="" type="checkbox"/> A preliminary amendment.</p> <p>14. <input type="checkbox"/> An Application Data Sheet under 37 CFR 1.76.</p> <p>15. <input type="checkbox"/> A substitute specification.</p> <p>16. <input type="checkbox"/> A power of attorney and/or address letter.</p> <p>17. <input checked="" type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 132 and 37 CFR 1.821-1825</p> <p>18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4)</p> <p>19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</p> <p>20. <input checked="" type="checkbox"/> Other items or information: copy of Notice (dated 3/13/06)</p>		

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.7)		INTERNATIONAL APPLICATION NO.	ATTORNEY'S DOCKET NUMBER									
10/560,280		PCT/JP2004/008224	40072-0026									
<p>21. The following fees are submitted:</p> <table> <tr> <td><input type="checkbox"/></td> <td>a) Basic national fee.....</td> <td>\$300.00</td> </tr> <tr> <td><input type="checkbox"/></td> <td>b) Examination fee .....</td> <td>\$200.00</td> </tr> <tr> <td><input type="checkbox"/></td> <td>c) Search fee.....</td> <td>\$500.00</td> </tr> </table>				<input type="checkbox"/>	a) Basic national fee.....	\$300.00	<input type="checkbox"/>	b) Examination fee .....	\$200.00	<input type="checkbox"/>	c) Search fee.....	\$500.00
<input type="checkbox"/>	a) Basic national fee.....	\$300.00										
<input type="checkbox"/>	b) Examination fee .....	\$200.00										
<input type="checkbox"/>	c) Search fee.....	\$500.00										
<b>TOTAL OF ABOVE CALCULATIONS =</b>												
<input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.												
<b>TOTAL SHEETS</b>	<b>EXTRA SHEETS</b>	<b>NUMBER EXTRA (of each additional 50 or fraction thereof rounded up to a whole number)</b>	<b>RATE</b>									
			-100 =      50 =      x \$250.00									
Surcharge of <b>\$130.00</b> for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)).												
<b>CLAIMS</b>	<b>NUMBER FILED</b>	<b>NUMBER EXTRA</b>	<b>RATE</b>									
Total claims	14 - 20 =	0	x \$50.00									
Independent claims	1 - 3 =	0	x \$200.00									
<b>MULTIPLE DEPENDENT CLAIM(S) (if applicable)</b>			+ \$360.0									
<b>SUBTOTAL =</b>												
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by ½.												
<b>SUBTOTAL =</b>												
Processing fee of <b>\$130.00</b> for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)). +												
<b>TOTAL NATIONAL FEE =</b>												
Fee for recording the enclose assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property												
<b>TOTAL FEES ENCLOSED =</b>			\$ 0 fees due									
			Amount to be refunded: \$									
			Amount to be charged: \$									
<p>a. <input type="checkbox"/> A check in the amount of _____ to cover the above fees is enclosed.</p> <p>b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees.</p> <p>A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment To Deposit Account No. <u>08-1641</u> A duplicate coy of this sheet is enclosed.</p> <p>d. <input type="checkbox"/> Fees are to be charged to a credit card. <b>WARNING: Information on this form may become public. Credit card information should not be included on this form.</b> Provide credit card information and authorization on PTO-2038.</p> <p>NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</p>												
<p>SEND ALL CORRESPONDENCE TO:</p> <p><i>Patricia D. Granados</i></p> <p>SIGNATURE</p> <p>HELLER EHRMAN LLP 1717 Rhode Island Avenue, N.W. Washington, D.C. 20036 Customer No.: 26633</p> <p>Patricia D. Granados</p> <p>NAME _____ Date _____</p> <p>REGISTRATION NO.: 33,683 April 26, 2006</p>												



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/560,280	Takeshi Tabira	40072-0026US

INTERNATIONAL APPLICATION NO.

PCT/JP04/08224

I.A. FILING DATE	PRIORITY DATE
06/11/2004	06/13/2003

26633  
 HELLER EHRMAN WHITE & MCAULIFFE LLP  
 1717 RHODE ISLAND AVE, NW  
 WASHINGTON, DC 20036-3001


**CONFIRMATION NO. 3468**  
**371 WITHDRAWAL NOTICE**



\*OC000000019637468\*

Date Mailed: 07/17/2006

**WITHDRAWAL OF PREVIOUSLY SENT NOTICE**



PAULETTE R KIDWELL

Telephone: (703) 308-9140 EXT 216

PART 1 - ATTORNEY/APPLICANT COPY

ATTACHMENT C